Literature DB >> 8912367

Dose-rate effects in targeted radiotherapy.

R G Dale1.   

Abstract

The physical dose delivered in radio-immunotherapy (RIT) may not, by itself, be a reliable indicator of the likely effectiveness of the treatment. Radiobiological considerations, in particular those relating to the dose-rate, are also very relevant. Dose-rate effects are important in conventional radiotherapy because of their ability to produce differential sparing effects between normal and malignant tissue. With targeted radiotherapy, in which dose-rates are likely to vary both spatially and temporally, the instantaneous dose-rate is additionally relevant since it determines whether or not any on-going clonogenic tumour re-population can be controlled. Therefore, for RIT in particular, there are two separate facets to the dose-rate effect, one concerned with the relative ability of different tissues to recover from radiation damage, the other concerned with the absolute ability to control concurrent tumour re-growth. In this article these two aspects are examined in terms of the linear-quadratic model and the implications assessed. Other radiobiological issues, such as re-oxygenation and cell cycle re-distribution are not discussed here.

Entities:  

Mesh:

Year:  1996        PMID: 8912367     DOI: 10.1088/0031-9155/41/10/001

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  21 in total

1.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.

Authors:  M Lassmann; C Chiesa; G Flux; M Bardiès
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-27       Impact factor: 9.236

2.  Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.

Authors:  Hong Song; Yong Du; George Sgouros; Andrew Prideaux; Eric Frey; Richard L Wahl
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Radiobiological considerations for radioembolization with 188Re-microspheres.

Authors:  Liane Oehme; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-19       Impact factor: 9.236

Review 4.  Linear quadratic and tumour control probability modelling in external beam radiotherapy.

Authors:  S F C O'Rourke; H McAneney; T Hillen
Journal:  J Math Biol       Date:  2008-09-30       Impact factor: 2.259

Review 5.  Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.

Authors:  Marta Cremonesi; Mahila Esmeralda Ferrari; Lisa Bodei; Carlo Chiesa; Anna Sarnelli; Cristina Garibaldi; Massimiliano Pacilio; Lidia Strigari; Paul Eugene Summers; Roberto Orecchia; Chiara Maria Grana; Francesca Botta
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-21       Impact factor: 9.236

6.  Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.

Authors:  C Chiesa; M Mira; M Maccauro; C Spreafico; R Romito; C Morosi; T Camerini; M Carrara; S Pellizzari; A Negri; G Aliberti; C Sposito; S Bhoori; A Facciorusso; E Civelli; R Lanocita; B Padovano; M Migliorisi; M C De Nile; E Seregni; A Marchianò; F Crippa; V Mazzaferro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-27       Impact factor: 9.236

7.  Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Authors:  C Chiesa; F Botta; A Coliva; M Maccauro; L Devizzi; A Guidetti; C Carlo-Stella; E Seregni; M A Gianni; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-20       Impact factor: 9.236

8.  Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.

Authors:  Sébastien Baechler; Robert F Hobbs; Andrew R Prideaux; Richard L Wahl; George Sgouros
Journal:  Med Phys       Date:  2008-03       Impact factor: 4.071

9.  Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment.

Authors:  Marta Cremonesi; Mahila Ferrari; Mirco Bartolomei; Franco Orsi; Guido Bonomo; Demetrio Aricò; Andrew Mallia; Concetta De Cicco; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-10       Impact factor: 9.236

10.  A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin).

Authors:  Massimiliano Pacilio; Margherita Betti; Francesco Cicone; Carolina Del Mastro; Livia Montani; Laura Chiacchiararelli; Alessia Monaco; Enrico Santini; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.